The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2017 | How can pregnancy in myeloproliferative neoplasms (MPNs) be managed?
Martin Griesshammer, MD, Johannes-Wesling Clinic Minden, Minden, Germany, discusses the management of myeloproliferative neoplasms (MPNs) in pregnant patients at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He speaks about the challenges of pregnancy in MPNs, and why there is an increased risk of thrombosis but also of bleeding. Prof. Griesshammer highlights that with management, a live birth rate of around 70% can be achieved. He concludes that individualized treatment is needed due to the differences in complications between patients, and that patients who require treatment need to be treated.
